Viswanath Devanarayan

发表

Figure 7: [Potency, MSR chart, and summary statistics for an assay with two controls.].

Benoit Beck, Yun-Fei Chen, Walthere Dere, 2012 .

Sitta Sittampalam, Viswanath Devanarayan, Karen L. Cox, 2014 .

Table 1: [Plate 1 layout for initial...].

Sitta Sittampalam, Viswanath Devanarayan, Karen L. Cox, 2014 .

2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3--LBA, biomarkers and immunogenicity).

Renuka Pillutla, Viswanath Devanarayan, An Song, 2015, Bioanalysis.

[Figure, Table 7: Validation Plate Layout.]

Sitta Sittampalam, Viswanath Devanarayan, Karen L. Cox, 2014 .

Table 5: [Example plate layout to increase calibration precision.].

Sitta Sittampalam, Viswanath Devanarayan, Karen L. Cox, 2014 .

Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development.

Lindsay King, Viswanath Devanarayan, Steve Keller, 2015, Bioanalysis.

Table 6: [Experimental plan from the second...].

Sitta Sittampalam, Viswanath Devanarayan, Karen L. Cox, 2014 .

Figure 5: [Standard Interleaved 384-well Format Plate Layouts.].

G. Sitta Sittampalam, Benoit Beck, Yun-Fei Chen, 2012 .

Table 4: [Results from Example 2: to...].

Sitta Sittampalam, Viswanath Devanarayan, Karen L. Cox, 2014 .

[Figure, Table 3: Plate layout to determine the capture and detection antibody concentrations.]

Sitta Sittampalam, Viswanath Devanarayan, Karen L. Cox, 2014 .

Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points

Viswanath Devanarayan, Rocco L. Brunelle, Wendell C. Smith, 2017, The AAPS Journal.

Intelligent and effective informatic deconvolution of “Big Data” and its future impact on the quantitative nature of neurodegenerative disease therapy

Viswanath Devanarayan, Hugo Geerts, Stuart Maudsley, 2018, Alzheimer's & Dementia.

Figure 10: [Potency and MSR chart for change in assay variability.].

Benoit Beck, Yun-Fei Chen, Walthere Dere, 2012 .

Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement

Viswanath Devanarayan, Russell Weiner, Chad Ray, 2006, Pharmaceutical Research.

Figure 8: [Potency and MSR chart illustrating assay drift.].

Benoit Beck, Yun-Fei Chen, Walthere Dere, 2012 .

Glossary of Quantitative Biology Terms

Sitta Sittampalam, Viswanath Devanarayan, Barry D. Sawyer, 2014 .

Figure 12: [Tier I validation study comparing...].

G. Sitta Sittampalam, Benoit Beck, Walthere Dere, 2012 .

Table 2: [MSR and LsA evaluation of...].

G. Sitta Sittampalam, Benoit Beck, Walthere Dere, 2012 .

META-ANALYSIS OF HETEROGENEOUS NETWORKS TO CONSTRUCT DE-NOVO META-NETWORKS FOR TARGET IDENTIFICATION IN ALZHEIMER’S DISEASE

Viswanath Devanarayan, Gyan P. Srivastava, 2018, Alzheimer's & Dementia.

Workshop Report: AAPS Workshop on Method Development, Validation, and Troubleshooting of Ligand-Binding Assays in the Regulated Environment

Binodh DeSilva, Viswanath Devanarayan, Lauren Stevenson, 2015, The AAPS Journal.

Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines

Viswanath Devanarayan, Saul H. Rosenberg, Paul E. Kroeger, 2010, Molecular Cancer Therapeutics.

Evaluation of Plasma Proteomic Data for Alzheimer Disease State Classification and for the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease

Viswanath Devanarayan, Daniel A. Llano, Adam J. Simon, 2013, Alzheimer disease and associated disorders.

Empirical simulation extrapolation for measurement error models with replicate measurements

Viswanath Devanarayan, Leonard A. Stefanski, L. Stefanski, 2002 .

Confirmatory reanalysis of incurred bioanalytical samples

Viswanath Devanarayan, V. Devanarayan, Mario L. Rocci, 2007, The AAPS Journal.

A hidden Markov model-based algorithm for identifying tumour subtype using array CGH data

Viswanath Devanarayan, Youping Deng, Linglin Xie, 2011, BMC Genomics.

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.

Viswanath Devanarayan, Michele Fiscella, Lakshmi Amaravadi, 2008, Journal of pharmaceutical and biomedical analysis.

Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum.

Viswanath Devanarayan, Ronald R Bowsher, Wendell C. Smith, 2005, Journal of pharmaceutical and biomedical analysis.

Evaluation of the plasma proteomics data from the ADNI database for Alzheimer's disease-state classification and prediction of 12-month progression from MCI to AD

Viswanath Devanarayan, Adam Simon, 2011, Alzheimer's & Dementia.

Minimum Significant Ratio of Selectivity Ratios (MSRSR) and Confidence in Ratio of Selectivity Ratios (CRSR)

Viswanath Devanarayan, Christopher M Harris, V. Devanarayan, 2012, Journal of biomolecular screening.

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.

Viswanath Devanarayan, Boris Gorovits, Michael Moxness, 2008, Journal of immunological methods.

Derivation of a New ADAS-cog Composite Using Tree-based Multivariate Analysis: Prediction of Conversion From Mild Cognitive Impairment to Alzheimer Disease

Viswanath Devanarayan, Daniel A Llano, D. Llano, 2011, Alzheimer disease and associated disorders.

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.

George Scott, Viswanath Devanarayan, Gopi Shankar, 2004, Journal of immunological methods.

Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge

Viswanath Devanarayan, Hugo Geerts, Stuart Maudsley, 2016, Alzheimer's & Dementia.

Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics.

Viswanath Devanarayan, An Song, Susan Kirshner, 2011, Journal of pharmaceutical and biomedical analysis.

Cut Points and Performance Characteristics for Anti‐Drug Antibody Assays

Viswanath Devanarayan, Michael G. Tovey, 2011 .

A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression

Viswanath Devanarayan, Daniel A Llano, D. Llano, 2017, PloS one.